Extended Data Fig. 10: No sign of acute liver or kidney injury are observed after i.v. injection KCZ@LNP or GGTi-2418@LNP. | Nature Cancer

Extended Data Fig. 10: No sign of acute liver or kidney injury are observed after i.v. injection KCZ@LNP or GGTi-2418@LNP.

From: Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxtecan

Extended Data Fig. 10

(a-c) C57BL/6 mice were i.v. administrated with GGTi-2418@LNP (20 mg/kg, once every day for 2 times) or KCZ@LNP (10 mg/kg, once every day for 2 times). At defined time points post-injection, the blood was collected for blood biochemistry examination (a-b), including liver function markers (ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; TP, total protein) and kidney function markers (CREA, creatinine; UREA, urea). The grey area is the normal range. The mice body weight was recorded every two days (c). Data are presented as mean ± SEM (n = 4/group). Statistical analysis was conducted using two-way ANOVA with Tukey’s multiple-comparison test (c).

Source data

Back to article page